The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
19-Sep-12
$130 million
Target:
Ramtron International Corporation
Acquiror:
Cypress Semiconductor Corporation
Advised Cypress Semiconductor Corporation, a leading provider of mixed-signal and programmable solutions worldwide, on its unsolicited acquisition of Ramtron International Corporation, a leading provider of ferroelectric random access memory (F-RAM) devices
02-Sep-12
$285 million
Target:
DMG Radio Australia, a subsidiary of Daily Mail and Guardian Trust Plc
Acquiror:
Illyria Pty
Advised Daily Mail and Guardian Trust plc (DMGT), on the sale of its remaining 50% interest in its Radio business in Australia to Illyria Pty, a private investment company of Lachlan Murdoch. The Radio operations comprise two national music networks in Australia
27-Aug-12
$1.1 billion
Target:
Deltek, Inc.
Acquiror:
Thoma Bravo, LLC
Advised Deltek, Inc., the leading global provider of enterprise software and information solutions for professional services firms and government contractors, on its acquisition by Thoma Bravo, LLC
21-Aug-12
$1.1 billion
Target:
Broadcast Rights for the National Rugby League
Acquiror:
Nine Network / Fox Sports
Advised the Australian Rugby League Commission on the sale of the Australian television broadcasting rights for the National Rugby League to Nine, a leading Free to Air broadcaster and Fox Sports, Australia’s largest pay TV broadcaster (partially owned by News Limited)
20-Aug-12
$7.3 billion
Target:
Coventry Health Care Inc.
Acquiror:
Aetna
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
13-Aug-12
$32 million
Target:
Journal Communications, Inc.
Advised the Board of Directors of Journal Communications, Inc., a diversified media company with newspaper and broadcasting interests, in connection with the repurchase of 100% of the issued and outstanding shares of its Class C Common Stock from successors to the Company’s founding family
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
30-Jul-12
$150 million
Target:
Alpine Access, Inc.
Acquiror:
SYKES Enterprises, Inc.
Advised SYKES Enterprises, a leading global provider of outsourced customer contact management solutions and services, on its acquisition of Alpine Access, a leader in at-Home customer contact management solutions and services
12-Jul-12
$5.0 billion
Target:
Aegis Group plc
Acquiror:
Dentsu Inc.
Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia
09-Jul-12
$4.7 billion
Target:
ASML Holding NV (minority stake)
Acquiror:
Customers including Intel Corporation, TSMC and Samsung Electronics
Advised the Supervisory Board of ASML on the establishment of a Customer Co-Investment Program including the issue of 23% equity stake and $1.7 billion of R&D funding
28-Jun-12
$275 million
Target:
Village Roadshow Entertainment Group
Advised Village Roadshow Entertainment Group on its $275 million mezzanine and equity capital raise from a group of investors
21-May-12
$NA
Target:
Robbins-Gioia Inc.
Acquiror:
Private Investors
Advised Informa plc on the sale of its subsidiary, Robbins-Gioia Inc., to a group of private investors
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
13-Dec-11
$345 million
Target:
Cabot Microelectronics Corporation
Advised Cabot Microelectronics Corporation on its new capital management initiative, including a leveraged recapitalization via a special dividend
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
27-Jul-11
$850 million
Target:
The Synovate Group
Acquiror:
Ipsos S.A.
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
24-May-11
$1.0 billion
Target:
New Zealand Ultra-Fast Broadband
Sole financial adviser to Crown Fibre Holdings (100% New Zealand Government owned entity) on the tender and negotiations for the investment of NZ$1.3 billion in a new ultra-fast broadband network in New Zealand, which includes agreements with Telecom Corporation of New Zealand, Christchurch City Holdings, WEL Networks and Northpower
13-May-11
$NA
Target:
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
14-Feb-11
$40.0 billion
Target:
Australian National Broadband Network
Greenhill acted as sole adviser to the Australian government in connection with the National Broadband Network, which represents the single largest infrastructure project in the country’s history
20-Dec-10
$370 million
Target:
One Communications Corp.
Acquiror:
EarthLink
Advised EarthLink, a provider of IP services to consumers and businesses, on its acquisition of One Communications, an integrated telecommunications solutions provider
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity